EMPEROR-Preserved

March 15, 2019

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  • Clinical Trial Information

    Trial Contact: Noel, Henry

    Trial Phone: 321.841.3686

  • IRB No: 18.024.02

    Protocol Abbrev: EMPEROR-Preserved

    Principal Investigator: Bhupinder R. Gupta, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: 2016-002278-11 EudraCT Number

    Treatment: Drug: Empagliflozin

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT03057951

  • Objective

    Demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms

  • Key Eligibility

    1. Heart Failure Class II-IV
    2. Preserved EF (>40%)
    3. Elevated NT-proBNP
    4. Oral Diuretics